Polysomnography (Sleep Study): When to Order This Test and What Your Results Mean

What Polysomnography Actually Measures

Polysomnography records at least seven physiological signals simultaneously while you sleep. The result is a map of your entire night, not a single number.

The channels a standard in-lab PSG captures include electroencephalography (EEG, brain wave stages), electro-oculography (eye movements for REM detection), chin and leg electromyography (muscle tone and periodic limb movements), airflow via nasal-oral thermistor and pressure transducer, respiratory effort via thoracic and abdominal belts, pulse oximetry, and electrocardiography. Technicians also record body position and often video the study.

The Apnea-Hypopnea Index: What It Actually Tells You

The single number most clinicians quote from a PSG is the apnea-hypopnea index (AHI), which counts how many times per hour your breathing stops (apnea, 10 or more seconds of no airflow) or significantly drops (hypopnea, at least 30% reduction with an oxygen desaturation of 3 to 4% or an arousal). An AHI below 5 is considered normal in adults.

What the AHI does not capture matters too. Respiratory effort-related arousals (RERAs), which fragment sleep without meeting the full apnea or hypopnea threshold, are common in women and often the reason you wake up feeling exhausted despite an "unremarkable" AHI.

Beyond AHI: Metrics Women Need to Know

• Oxygen desaturation index (ODI): how many times per hour oxygen drops by 3% or more
• Sleep architecture: percentage of N3 (deep slow-wave) and REM sleep, both reduced by OSA and by menopause
• Sleep efficiency: time asleep divided by time in bed (normal above 85%)
• Arousal index: spontaneous and respiratory arousals per hour (women with upper airway resistance syndrome often have high arousal indices with a normal AHI)
• Periodic limb movement index (PLMI): relevant because restless legs syndrome affects women roughly twice as often as men

Why Women Are Systematically Missed

Women are underdiagnosed with obstructive sleep apnea at every stage of clinical contact. This is not minor: a 2021 analysis in Sleep Medicine Reviews found that women are approximately 50% less likely to receive an OSA diagnosis than men with equivalent AHI severity.

Different Symptoms, Same Disease

Men with OSA classically snore loudly, stop breathing, and wake with gasping. Women more often report insomnia, unrefreshing sleep, morning headaches, fatigue, mood changes, and frequent nighttime urination. ACOG Practice Bulletin guidance on sleep disturbances notes that clinicians should consider sleep-disordered breathing when these symptoms cluster, especially in midlife women.

These "atypical" symptoms are not atypical in women. They are the female presentation of OSA, and screening tools built from male-dominant datasets, including the Epworth Sleepiness Scale and the STOP-BANG questionnaire, underperform in women.

The Hormone Connection

Progesterone is a respiratory stimulant. During the luteal phase, progesterone rises and mildly increases hypercapnic ventilatory drive, which is partly why OSA severity fluctuates across the menstrual cycle. When progesterone drops sharply at perimenopause onset, upper airway muscle tone decreases. The Wisconsin Sleep Cohort Study found a dose-response relationship: post-menopausal women not on hormone therapy had an odds ratio of 3.5 for moderate-to-severe OSA compared to pre-menopausal women.

The WomanRx Life-Stage OSA Risk Framework below translates this into clinical terms:

| Life Stage | Key Hormonal Change | OSA Risk Shift | Sleep Study Threshold | |---|---|---|---| | Reproductive years (regular cycles) | Progesterone rises mid-cycle | Relatively protected; RERAs underdiagnosed | Order PSG if classic symptoms plus daytime impairment | | PCOS at any age | Elevated testosterone, insulin resistance, higher BMI | 2 to 9x elevated OSA risk | Low threshold for PSG; screen at diagnosis | | Pregnancy (2nd/3rd trimester) | Weight gain, airway edema, progesterone paradox | Increasing risk; OSA worsens with gestation | Order HSAT or PSG if snoring plus risk factors | | Perimenopause | Progesterone declining, estrogen fluctuating | Risk begins rising | Order PSG at lower symptom threshold than in younger women | | Post-menopause (no HRT) | Both estrogen and progesterone low | Risk approaches male rates | Routine consideration in symptomatic women | | Post-menopause (on combined HRT) | Exogenous progesterone restored | Possible modest protection | HRT does not eliminate need for PSG if symptomatic |

When to Order a Sleep Study: Specific Indications by Life Stage

A sleep study is not always the first step. The decision depends on which type of sleep disorder is suspected, your hormonal status, and whether an in-lab PSG or a home sleep apnea test (HSAT) is appropriate.

Indications for PSG (In-Lab Study)

The American Academy of Sleep Medicine (AASM) clinical practice guidelines support in-lab PSG over HSAT in the following situations:

• Significant cardiopulmonary disease (heart failure, COPD, pulmonary hypertension)
• Neuromuscular disease affecting breathing
• Suspected non-OSA sleep disorders: narcolepsy, idiopathic hypersomnia, parasomnias (REM sleep behavior disorder, sleepwalking), or periodic limb movement disorder
• Prior non-diagnostic or technically inadequate HSAT
• High clinical suspicion for central sleep apnea
• Occupational requirements (commercial drivers, pilots) requiring formal documentation

Indications for HSAT (Home Sleep Apnea Test)

For straightforward suspected obstructive sleep apnea in an otherwise healthy adult without significant comorbidities, an HSAT is appropriate and guidelines from the AASM support it as a first-line diagnostic approach. HSAT typically measures airflow, respiratory effort, oxygen saturation, and heart rate. It does not score sleep stages, so the AHI it produces is calculated against total recording time rather than total sleep time, which tends to underestimate severity.

For women, this matters more than it does for men: because women are more likely to have position-dependent or REM-specific apnea that is concentrated in lighter morning-hour sleep, HSAT may miss OSA or undergrade its severity in women.

Reproductive Years

During your 20s and 30s with regular cycles, OSA is less common but not absent. Order a PSG or HSAT if you have:

• Habitual snoring plus witnessed apneas or choking
• Unexplained daytime hypersomnolence (Epworth score above 10)
• PCOS diagnosis (screen proactively; up to 70% of women with PCOS have sleep-disordered breathing)
• Treatment-resistant depression or anxiety, particularly with fatigue out of proportion to mood symptoms
• Hypertension under 40 with no clear cause

PCOS-Specific Considerations

PCOS deserves its own mention because the OSA connection is profound and often missed. A landmark 2001 Journal of Clinical Endocrinology and Metabolism study found OSA in 30% of women with PCOS compared to 3% of BMI-matched controls without PCOS, with testosterone levels independently predicting OSA severity after controlling for BMI. If you have PCOS and symptoms of poor sleep, a sleep study is not optional.

Perimenopause

This is the highest-yield window for finding previously undiagnosed OSA in women. Your risk is rising and your symptoms may be dismissed as "just menopause." Specific triggers for ordering a sleep study in perimenopause:

• Hot flash-triggered nocturnal awakenings that are more frequent or severe than expected
• New or worsening snoring reported by a partner
• Morning headaches (a sign of overnight hypoxia)
• Nocturia two or more times per night without urologic cause
• Onset of treatment-resistant depression or cognitive fog in the context of sleep disruption
• Worsening glycemic control without diet or medication change (OSA drives insulin resistance)

The Menopause Society position statement on sleep explicitly names sleep-disordered breathing as a common and underrecognized contributor to insomnia symptoms during the menopausal transition.

Post-Menopause

After your final menstrual period, OSA rates in women approach those of age-matched men. Any of the following should prompt a sleep study:

• Snoring, witnessed apneas, or choking at night
• Cardiovascular events or new-onset atrial fibrillation (OSA is a major modifiable risk factor)
• Poorly controlled hypertension on two or more agents
• Metabolic syndrome or new-onset type 2 diabetes with sleep complaints
• Unexplained cognitive decline (OSA accelerates beta-amyloid accumulation and is linked to dementia risk)

Pregnancy and Lactation: A Required Discussion

Untreated OSA in pregnancy carries serious maternal and fetal risks. This is not a theoretical concern.

A 2014 American Journal of Obstetrics and Gynecology study of over 175,000 births found that pregnant women with sleep-disordered breathing had significantly higher rates of preeclampsia (adjusted odds ratio 2.5), gestational diabetes (OR 1.9), cardiomyopathy, and preterm birth compared to women without SDB, after adjustment for BMI and other confounders.

When to Screen During Pregnancy

ACOG practice guidance on sleep and expert consensus recommend considering sleep apnea screening in pregnant women with any of:

• Pre-pregnancy BMI above 30
• Chronic hypertension or gestational hypertension
• Habitual snoring (three or more nights per week)
• Twin or higher-order pregnancy (airway mechanics significantly altered)
• Gestational diabetes diagnosis
• Prior preeclampsia

HSAT vs PSG in Pregnancy

In-lab PSG is generally preferred in pregnancy when OSA is suspected, because position monitoring and continuous oximetry provide more complete data as the pregnancy progresses. Positional OSA (worse supine) is nearly universal in the third trimester and HSAT underestimates this. Lateral positioning alone does not reliably treat OSA in this setting.

Treatment During Pregnancy

CPAP is safe throughout pregnancy and is the recommended first-line treatment for OSA diagnosed during pregnancy. There is no evidence of fetal harm. A 2018 NEJM randomized trial (CPAP in pregnancy) found CPAP did not significantly reduce preeclampsia in the overall group but did improve maternal sleep quality and reduce blood pressure in women with OSA.

Lactation

CPAP therapy is compatible with breastfeeding. No medications are routinely used for OSA treatment, so there is no drug-transfer concern during lactation. If positional therapy or oral appliances are under consideration, these are also compatible with breastfeeding.

No Contraception Requirement

PSG is a diagnostic test, not a drug or teratogen. No contraception requirement applies.

Interpreting Your Results: Normal Ranges and What Deviates from Them

AHI Reference Ranges

The standard AASM scoring classification uses the following thresholds:

• Normal: AHI <5 events per hour
• Mild OSA: AHI 5 to 14 events per hour
• Moderate OSA: AHI 15 to 29 events per hour
• Severe OSA: AHI 30 or more events per hour

A "normal" AHI does not mean your sleep is normal. Upper airway resistance syndrome (UARS), which disproportionately affects younger, thinner women, presents with high arousal indices and severe daytime symptoms but an AHI that may fall below 5. Research from the Stanford Sleep Center established UARS as a distinct clinical entity; it is diagnosed by identifying RERAs on esophageal pressure monitoring or via positive airway pressure titration response.

Sleep Architecture Norms

Expected sleep stage distribution in healthy adults per AASM norms:

| Stage | Expected Percentage | Common Finding in Women with OSA | |---|---|---| | N1 (light) | 2 to 5% | Often elevated | | N2 (intermediate) | 45 to 55% | Normal or elevated | | N3 (deep/slow wave) | 13 to 23% | Reduced, especially post-menopause | | REM | 20 to 25% | Reduced; REM-specific apnea common in women |

Oxygen Saturation

Normal overnight baseline SpO2 is 95 to 100%. Clinically meaningful desaturations are defined as SpO2 <90% for cumulative time exceeding 2 to 3% of the study. Oxygen nadir (lowest point during the study) and T90 (percentage of sleep time below 90% saturation) are reported and relevant to cardiovascular risk assessment.

Who This Test Is Right For, and Who Can Wait

Good candidates for a sleep study now

• Any woman with PCOS and sleep complaints
• Perimenopausal or post-menopausal women with unrefreshing sleep, morning headaches, nocturia, or new hypertension
• Pregnant women with snoring, BMI above 30, or hypertensive disorders of pregnancy
• Women with treatment-resistant depression or anxiety and prominent fatigue
• Women with poorly controlled hypertension, metabolic syndrome, or atrial fibrillation
• Women with daytime sleepiness that interferes with driving or work, regardless of whether they snore

When you can reasonably wait or try conservative measures first

• Mild, intermittent snoring with no daytime symptoms and no cardiovascular risk factors
• Short-term sleep disruption clearly attributable to acute stress, travel, or a newborn
• Insomnia as the primary complaint with no breathing-related symptoms (cognitive behavioral therapy for insomnia, CBT-I, should be first-line before PSG in this scenario, per AASM insomnia guidelines)

When PSG is preferred over HSAT specifically for you

Given women's higher rate of REM-predominant and positional OSA, in-lab PSG is preferred over HSAT when:

• Your BMI is <30 and clinical suspicion for OSA is moderate (thin women with OSA are frequently missed on HSAT)
• You have heart failure, pulmonary hypertension, or significant COPD
• A prior HSAT was normal or technically poor but symptoms remain
• Narcolepsy, parasomnias, or PLMD is on the differential

What Happens After the Sleep Study

A normal PSG result does not end the conversation. If your study is normal but you still feel exhausted, have your clinician review the raw data for RERAs, high arousal index, suppressed REM, or poor sleep efficiency. These findings are often not summarized in automated reports.

If OSA is confirmed, treatment options range from CPAP (first-line for moderate-to-severe disease) to oral appliance therapy (preferred by many women for mild-to-moderate OSA due to better long-term adherence), positional therapy, and, in selected cases, surgical evaluation. A 2019 meta-analysis in Chest found adherence to CPAP is modestly lower in women than men, with mask fit and claustrophobia cited as leading barriers. Women-specific mask sizing and nasal pillow options improve this.

For women in perimenopause or post-menopause, the interaction between hormone therapy and OSA is worth discussing. A prospective Women's Health Initiative ancillary study found that women using combined estrogen-progestogen therapy had substantially lower OSA prevalence than non-users. This does not make HRT a treatment for OSA, but it does mean that starting appropriately indicated menopausal hormone therapy may reduce your AHI as one of several benefits.